Bernd Metzner
About
Bernd Metzner is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Bernd Metzner has authored 126 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Pathology and Forensic Medicine, 66 papers in Oncology and 36 papers in Genetics. Recurrent topics in Bernd Metzner's work include Lymphoma Diagnosis and Treatment (70 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Viral-associated cancers and disorders (24 papers). Bernd Metzner is often cited by papers focused on Lymphoma Diagnosis and Treatment (70 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Viral-associated cancers and disorders (24 papers). Bernd Metzner collaborates with scholars based in Germany, United States and Netherlands. Bernd Metzner's co-authors include Michael Pfreundschuh, Martin Dreyling, Wolfgang Hiddemann, Michael Unterhalt, Norma Peter, Eva Hoster, Carsten Bokemeyer, Norbert Schmitz, Marcel Reiser and Hermann Einsele and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Bernd Metzner
124 papers receiving 5.5k citations
Hit Papers
Peers
Bernd Metzner
Carol S. Portlock United States
Stefano Luminari Italy
Catherine Sebban France
Dok Hyun Yoon South Korea
John Sweetenham United States
Umberto Vitolo Italy
Luis F. Porrata United States
Marine Diviné France
Morton Coleman United States
P Lederlin France
Citations per year, relative to Bernd Metzner Bernd Metzner (= 1×)
peers
Carol S. Portlock
Countries citing papers authored by Bernd Metzner
Since
Specialization
Citations
This map shows the geographic impact of Bernd Metzner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Metzner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Metzner more than expected).
Fields of papers citing papers by Bernd Metzner
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Bernd Metzner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Metzner. The network helps show where Bernd Metzner may publish in the future.
Co-authorship network of co-authors of Bernd Metzner
This figure shows the co-authorship network connecting the top 25 collaborators of Bernd Metzner. A scholar is included among the top collaborators of Bernd Metzner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernd Metzner. Bernd Metzner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Metzner, Bernd, Thomas Müller, Jochen Casper, et al.. (2023). Long‐term outcome in patients with mantle cell lymphoma following high‐dose therapy and autologous stem cell transplantation. European Journal Of Haematology. 111(2). 220–228.
2.
Straka, Christian, Hans Salwender, Stefan Knop, et al.. (2021). Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. European Journal Of Haematology. 107(5). 529–542.
3.
Pettengell, Ruth, Ariane Boumendil, Roderick J. Johnson, et al.. (2021). Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial. Bone Marrow Transplantation. 56(6). 1413–1421.
4.
Metzner, Bernd, Thomas Müller, Jochen Casper, et al.. (2021). Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease. Strahlentherapie und Onkologie. 198(1). 39–46.
5.
Jurinović, Vindi, Bernd Metzner, Michael Pfreundschuh, et al.. (2018). Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. Biology of Blood and Marrow Transplantation. 24(6). 1172–1179.
6.
Sasse, Stephanie, Horst Müller, Lenka Šmardová, et al.. (2015). Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leukemia & lymphoma. 57(5). 1067–1073.
7.
Pettengell, Ruth, Norbert Schmitz, Christian Gisselbrecht, et al.. (2013). Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology. 31(13). 1624–1630.
8.
Metzner, Bernd, Christiane Pott, Thomas Müller, et al.. (2013). Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation. Annals of Oncology. 24(6). 1609–1615.
9.
Korfel, Agnieszka, Thomas Elter, E. Thiel, et al.. (2012). Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 98(3). 364–370.
10.
Metzner, Bernd, et al.. (2011). Long-Term Remissions in Metastatic Malignant Melanoma Following Chemotherapy and Tamoxifen Maintenance. Onkologie. 34(4). 208–209.
11.
Schmitz, Norbert, Lorenz Trümper, Marita Ziepert, et al.. (2010). Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 116(18). 3418–3425.
12.
Glaß, B., Marita Ziepert, Marcel Reiser, et al.. (2010). High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Annals of Oncology. 21(11). 2255–2261.
13.
Trümper, Lorenz, C. Zwick, Marita Ziepert, et al.. (2008). Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Annals of Oncology. 19(3). 538–544.
14.
Gluz, Oleg, Ulrike Nitz, Nadia Harbeck, et al.. (2008). Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Annals of Oncology. 19(5). 861–870.
15.
Josting, Andreas, Christian Rudolph, MY Mapara, et al.. (2004). Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Annals of Oncology. 16(1). 116–123.
16.
Kollmannsberger, Christian, N. Schleucher, Oliver Rick, et al.. (2003). Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support. European Journal of Cancer. 39(6). 775–782.
17.
Forstpointner, Roswitha, Roland Repp, Sandra Hermann, et al.. (2002). Rituximab zur Remissionsinduktion bei rezidivierten und refraktaeren indolenten Lymphomen und Mantelzell-Lymphomen: Ergebnisse einer prospektiv randomisierten Studie der deutschen Studiengruppe fuer niedrig maligne Lymphome (GLSG). DMW - Deutsche Medizinische Wochenschrift. 127(43). 2253–2258.
18.
Probst‐Kepper, Michael, Andres Jan Schrader, Jan Buer, et al.. (1997). Detection of melanoma cells in peripheral blood stem cell harvests of patients with progressive metastatic malignant melanoma. British Journal of Haematology. 98(2). 488–491.
19.
Bokemeyer, Carsten, Hans‐Joachim Schmoll, Bernd Metzner, et al.. (1993). Comparison of 5 vs 10 μg/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer. Annals of Hematology. 67(2). 75–79.
20.
Bokemeyer, C., Hans‐Joachim Schmoll, A. Harstrick, et al.. (1993). A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. European Journal of Cancer. 29(16). 2225–2231.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Carol S. Portlock Breakdown of academic impact, for papers by Stefano Luminari Breakdown of academic impact, for papers by Catherine Sebban Breakdown of academic impact, for papers by Dok Hyun Yoon Breakdown of academic impact, for papers by John Sweetenham Breakdown of academic impact, for papers by Umberto Vitolo Breakdown of academic impact, for papers by Luis F. Porrata Breakdown of academic impact, for papers by Marine Diviné Breakdown of academic impact, for papers by Morton Coleman Breakdown of academic impact, for papers by P Lederlin